ZNF503-AS2 had predictive value for chemotherapy and immunotherapy in glioma. by Yibo Wu (788885)

“…NS, not statistically significant; * <i>P</i> < 0.05; ** <i>P</i> < 0.01; *** <i>P</i> < 0.001.…”

Scale and environmental data for the analysis of year class growth of coregonids from Lake Starnberg by Maxim Teichert (20796416)

“…During the observed period, phosphorus concentrations decreased, indicating reduced nutrient availability, whereas spring temperatures showed no significant long-term trend. …”

Validation of an abortive response with elevated NF-κB activity distinct from full lytic reactivation. by Elliott D. SoRelle (6527681)

“…Asterisks denote significantly decreased frequencies of <i>CD38</i>⁺ cells and increased frequencies of <i>BCL2A1</i>⁺ cells upon 4HT and 4HT+PAA treatment versus respective control treatments (n = 3 per condition; two-tailed Welch’s t-test; **p<0.01). …”

Phage–antibiotic interactions are determined by the antibiotic, not the phage. by Yuval Mulla (12734528)

“…Nitrofurantoin shows significantly more synergistic interactions than doxycycline (<i>p</i> = 0.008, Wilcoxon signed-rank test). …”

CLAD_sequence_files by Ryan Hunter (21714311)

“…</b>BALF metabolomes varied by underlying disease state, with AATD LT recipients being particularly distinctive (PERMANOVA, <i>p</i>= 0.001, F= 3.91). We also found a significant association with the final CLAD severity score (RF variance explained = 11.08%, PERMANOVA, <i>p</i>=0.001), especially those with underlying CF. …”

De-repression of endogenous retroelements triggers viral mimicry, interferon, and cytokine response. by Sarfraz Shafiq (13259589)

“…Variance stabilizing transformation (VST) counts from RNA-seq data (<i>n</i> = 3 each genotype; Bst2 <i>p</i> = 0.007, Ch25h <i>p</i> = 0.022, Ifit1 <i>p</i> = 0.012, Ifit3 <i>p</i> = 0.003, Ifit3b <i>p</i> = 0.006, Ifitm3 <i>p</i> = 0.004, Isg15 <i>p</i> = 0.037, Isg20 <i>p</i> = 0.009, Mx1 <i>p</i> = 0.006, Mx2 <i>p</i> = 0.006, Oas1a <i>p</i> = 0.001, Oas1b <i>p</i> = 0.007, Oas1g <i>p</i> = 0.002, Oas2 <i>p</i> = 0.002, Oas3 <i>p</i> = 0.015, Oasl1 <i>p</i> = 0.003, Oasl2 <i>p</i> = 0.004, Pml <i>p</i> = 0.007, Rsad2 <i>p</i> = 0.006, Student <i>T</i> test). …”

Ultimate Lateral resistance of Tetrapod Pile Foundation in Rate-dependent and Strain-softening Clay by Zi-hao Zhao (21085578)

“…The effect of the reciprocal of soil sensitivity is more significant, while the strain rate <b>exhibits</b> a linear positive interaction with the ultimate lateral resistance. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”

Table 4_The boundaries between PML and PML-IRIS: difficult to define, pathology may predict.docx by Jiamin Chen (388522)

“…</p>Results<p>Notably, 63.2% (12/19) of them had blood CD4+ T-cell counts < 200 cells/μl, and 36.8% (7/19) had ≥ 200 cells/μl. 52.9% (9/17) of the patients had elevated CSF protein, 5.3% (1/19) had decreased CSF glucose. Statistical analysis revealed significant correlations between mass effect and both blood CD4+ T-cell counts (P = 0.022) and CSF protein levels (P < 0.001). …”

Table 2_The boundaries between PML and PML-IRIS: difficult to define, pathology may predict.docx by Jiamin Chen (388522)

“…</p>Results<p>Notably, 63.2% (12/19) of them had blood CD4+ T-cell counts < 200 cells/μl, and 36.8% (7/19) had ≥ 200 cells/μl. 52.9% (9/17) of the patients had elevated CSF protein, 5.3% (1/19) had decreased CSF glucose. Statistical analysis revealed significant correlations between mass effect and both blood CD4+ T-cell counts (P = 0.022) and CSF protein levels (P < 0.001). …”